Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688011 · ClinicalTrials.gov registry record
Connect® Myeloid Disease Registry
A clinical trial, sponsored by Celgene.
- Terminated
- Registry status
- 2,013
- Enrollment target
NCT01688011: Clinical Trial study, sponsored by Celgene.
NCT01688011 is a clinical trial that was terminated before completion, run by Celgene. The registered enrollment target is 2,013 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01688011 was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- 2,013 participants
- Enrollment target
Study Summary
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Primary Outcome
Describe demographics, baseline characteristics and clinical outcomes of the patients with LR or HR MDS, ICUS, and AML.
Interventions
- DRUG Luspatercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,013 participants |
| Start Date | 2013-12-12 |
| Est. Completion | 2024-10-18 |
Why NCT01688011 stopped before completion
NCT01688011 is an observational study that tracks outcomes without assigning an intervention. Its 2,013 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Luspatercept is the first listed.
NCT01688011 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01688011 about?
NCT01688011 is a clinical study titled "Connect® Myeloid Disease Registry". The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular marke...
What is the current status of trial NCT01688011?
This trial is currently terminated. The enrollment target is 2,013 participants. The study started on 2013-12-12. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT01688011?
The interventions under investigation include: Luspatercept (DRUG).
Who is sponsoring clinical trial NCT01688011?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI